A Study To Estimate The Amount Of CP-690,550 (Study Drug) That Is Absorbed Into The Blood Of Healthy Subjects Following Oral Administration Of CP-690,550 In Tablet Form

• Drug: Tasocitinib 10 mg oral tablet
  
  Treatment A: Single-dose of tasocitinib (CP-690,550) (10 mg) in the form of an oral tablet
• Drug: Tasocitinib 10 mg IV Infusion
  
  Treatment B: Single-dose of tasocitinib (CP-690,550) (10 mg) in the form of a 30 minute intravenous infusion

• Experimental: Treatment A: Tasocitinib 10 mg oral tablet
  
  Intervention: Drug: Tasocitinib 10 mg oral tablet
• Experimental: Treatment B: Tasocitinib 10 mg IV Infusion
  
  Intervention: Drug: Tasocitinib 10 mg IV Infusion

Inclusion Criteria:

• Healthy male and/or female (non childbearing potential)
• Subjects between the ages of 21 and 55 years, inclusive
• Body Mass Index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight >50 kg (110 lbs)
• No evidence of active or latent or inadequately treated infection with Mycobacterium tuberculosis (TB)

Exclusion Criteria:

• Evidence or history of any clinically significant illness, medical condition, or disease.

  2. Evidence or history of any clinically significant infections within the past 3 months.

  3. Use of tobacco- or nicotine-containing products in excess of the equivalent of 5 cigarettes per day.